Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
THC's Cash-to-Debt is ranked lower than
92% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.37 vs. THC: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
THC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.05 Max: 0.39
Current: 0.03
0
0.39
Debt-to-Equity 620.04
THC's Debt-to-Equity is ranked lower than
99% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 0.63 vs. THC: 620.04 )
Ranked among companies with meaningful Debt-to-Equity only.
THC' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.57  Med: 1.64 Max: 620.04
Current: 620.04
0.57
620.04
Debt-to-EBITDA 9.25
THC's Debt-to-EBITDA is ranked lower than
80% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 2.82 vs. THC: 9.25 )
Ranked among companies with meaningful Debt-to-EBITDA only.
THC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.02  Med: 6.15 Max: 12.6
Current: 9.25
4.02
12.6
Interest Coverage 0.86
THC's Interest Coverage is ranked lower than
92% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 7.55 vs. THC: 0.86 )
Ranked among companies with meaningful Interest Coverage only.
THC' s Interest Coverage Range Over the Past 10 Years
Min: 0.66  Med: 1.24 Max: 1.82
Current: 0.86
0.66
1.82
Piotroski F-Score: 3
Altman Z-Score: 0.89
WACC vs ROIC
4.51%
20.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.62
THC's Operating Margin % is ranked lower than
54% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. THC: 4.62 )
Ranked among companies with meaningful Operating Margin % only.
THC' s Operating Margin % Range Over the Past 10 Years
Min: 3.41  Med: 5.98 Max: 8.21
Current: 4.62
3.41
8.21
Net Margin % -2.91
THC's Net Margin % is ranked lower than
76% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 4.16 vs. THC: -2.91 )
Ranked among companies with meaningful Net Margin % only.
THC' s Net Margin % Range Over the Past 10 Years
Min: -2.91  Med: 0.18 Max: 13.5
Current: -2.91
-2.91
13.5
ROE % -156.32
THC's ROE % is ranked lower than
94% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 9.23 vs. THC: -156.32 )
Ranked among companies with meaningful ROE % only.
THC' s ROE % Range Over the Past 10 Years
Min: -156.32  Med: 2.68 Max: 92.79
Current: -156.32
-156.32
92.79
ROA % -2.28
THC's ROA % is ranked lower than
75% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. THC: -2.28 )
Ranked among companies with meaningful ROA % only.
THC' s ROA % Range Over the Past 10 Years
Min: -2.28  Med: 0.19 Max: 13.89
Current: -2.28
-2.28
13.89
ROC (Joel Greenblatt) % 8.65
THC's ROC (Joel Greenblatt) % is ranked lower than
51% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. THC: 8.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
THC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.8  Med: 12.1 Max: 15.25
Current: 8.65
4.8
15.25
3-Year Revenue Growth Rate 21.90
THC's 3-Year Revenue Growth Rate is ranked higher than
87% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. THC: 21.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
THC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.7  Med: 0.3 Max: 32.4
Current: 21.9
-13.7
32.4
3-Year EBITDA Growth Rate 35.20
THC's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. THC: 35.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
THC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.1  Med: 9.4 Max: 37.9
Current: 35.2
-47.1
37.9
3-Year EPS without NRI Growth Rate 15.80
THC's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 163 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. THC: 15.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
THC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -72.8  Med: -0.4 Max: 57
Current: 15.8
-72.8
57
GuruFocus has detected 5 Warning Signs with Tenet Healthcare Corp THC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» THC's 30-Y Financials

Financials (Next Earnings Date: 2018-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

THC Guru Trades in Q4 2016

Michael Price 250,000 sh (New)
Jim Simons 1,325,875 sh (New)
George Soros 13,500 sh (New)
Paul Singer 1,494,358 sh (New)
Larry Robbins 17,890,230 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli Sold Out
Paul Tudor Jones 24,300 sh (-46.93%)
Steven Cohen 5,300 sh (-98.72%)
» More
Q1 2017

THC Guru Trades in Q1 2017

Jeremy Grantham 287,400 sh (New)
George Soros 18,400 sh (+36.30%)
Larry Robbins 17,890,230 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Paul Singer Sold Out
Michael Price 55,000 sh (-78.00%)
» More
Q2 2017

THC Guru Trades in Q2 2017

First Eagle Investment 778,655 sh (New)
Michael Price 97,224 sh (+76.77%)
Larry Robbins 17,890,230 sh (unchged)
Jeremy Grantham 287,400 sh (unchged)
George Soros Sold Out
» More
Q3 2017

THC Guru Trades in Q3 2017

Steven Cohen 282,435 sh (New)
Joel Greenblatt 80,389 sh (New)
Larry Robbins 17,890,230 sh (unchged)
First Eagle Investment Sold Out
Michael Price Sold Out
Jeremy Grantham 238,900 sh (-16.88%)
» More
» Details

Insider Trades

Latest Guru Trades with THC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 New Buy0.02%$12.65 - $21.11 $ 13.24-22%80,389
Michael Price 2017-09-30 Sold Out 0.24%$12.65 - $21.11 $ 13.24-22%0
First Eagle Investment 2017-09-30 Sold Out 0.04%$12.65 - $21.11 $ 13.24-22%0
First Eagle Investment 2017-06-30 New Buy0.04%$14.99 - $19.67 $ 13.24-24%778,655
Michael Price 2017-06-30 Add 76.77%0.1%$14.99 - $19.67 $ 13.24-24%97,224
George Soros 2017-06-30 Sold Out 0.01%$14.99 - $19.67 $ 13.24-24%0
Michael Price 2017-03-31 Reduce -78.00%0.35%$15.4 - $22.67 $ 13.24-29%55,000
George Soros 2017-03-31 Add 36.30%$15.4 - $22.67 $ 13.24-29%18,400
Michael Price 2016-12-31 New Buy0.45%$14.38 - $23.82 $ 13.24-26%250,000
George Soros 2016-12-31 New Buy0.01%$14.38 - $23.82 $ 13.24-26%13,500
Joel Greenblatt 2016-12-31 Sold Out 0.01%$14.38 - $23.82 $ 13.24-26%0
Mario Gabelli 2016-12-31 Sold Out $14.38 - $23.82 $ 13.24-26%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 622110    SIC: 8062
Compare:TSE:7716, ASX:PRY, SAU:4009, NAS:LHCG, BKK:BCH, SGX:BSL, BKK:SVH, BOM:532843, LSE:SPI, BKK:VIBHA, SAU:4007, BKK:RAM, XKLS:5878, SAU:4004, NAS:AMED, HKSE:01515, NSE:NH, ISX:SILO, XSWX:AEVS, NAS:TVTY » details
Traded in other countries:THC1.Germany,
Headquarter Location:USA
Tenet Healthcare Corp is a healthcare service provider in the US. The company operates acute-care hospitals that includes ambulatory surgery centers, diagnostic imaging centers, and urgent care centers across United States.

Based in Dallas, Tenet Healthcare is one of the largest acute-care firms in the U.S., accounting for roughly 2% of the country's hospital admissions. It operates 79 acute-care hospitals with more than 20,000 beds, as well as over 475 ambulatory surgery centers, diagnostic imaging centers, and urgent care centers, and a revenue cycle subsidiary called Conifer. Tenet has facilities in numerous states, with most of its total operations in California, Florida, and Texas. Outpatient services make up about 36% of Tenet's patient revenue.

Top Ranked Articles about Tenet Healthcare Corp

New Research Coverage Highlights Colgate-Palmolive, Tenet Healthcare, Mastercard, Dynegy, Symantec, and The Williams Companies – Consolidated Revenues, Company Growth, and Expectations for 2018
Investors: Covered-call reports for Box, Foot Locker, Fabrinet, Intellia Therapeutics and Tenet Healthcare
WellCare Completes Acquisition Of Arizona Medicaid Assets Of Phoenix Health Plan
Amedisys Announces Definitive Agreement to Acquire Six Home Health and Hospice Care Centers from Tenet Healthcare

BATON ROUGE, La., March 01, 2017 (GLOBE NEWSWIRE) --  Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home health care, hospice and personal care companies, today announced that it has signed a definitive agreement to acquire Tenet Healthcare’s (:THC) home health and hospice operations in Arizona, Illinois, Massachusetts and Texas.
“This acquisition gives Amedisys an incredible opportunity to continue our goal of providing high-quality post-acute services in key markets,” stated President and Chief Executive Officer Paul Kusserow. “We look forward to the opportunity to work with Tenet in these markets to improve the delivery of care and management of patients across the care continuum.” “Amedisys shares our commitment to serving patients, employees and the community,” stated Trevor Fetter, Chairman and Chief Executive Officer of Tenet Healthcare. “We are transferring these local operations of healthcare service providers to Amedisys so that high quality home health and hospice services will continue to be available within the communities they serve.” Since December 2015, Amedisys has announced six acquisitions, deploying approximately $125 million in capital and contributing approximately $145 million in revenue.  Forward-Looking Statements: When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business efficiently, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 16,000 employees, in 420 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.  About Tenet Healthcare
Tenet Healthcare Corporation is a diversified healthcare services company with 130,000 employees united around a common mission: to help people live happier, healthier lives. Through its subsidiaries, partnerships and joint ventures, including United Surgical Partners International, the company operates 80 general acute care hospitals, 20 short-stay surgical hospitals and approximately 470 outpatient centers in the United States, as well as nine facilities in the United Kingdom. Tenet’s Conifer Health Solutions subsidiary provides technology-enabled performance improvement and health management solutions to hospitals, health systems, integrated delivery networks, physician groups, self-insured organizations and health plans. For more information, please visit www.tenethealth.com
Kendra Kimmons 
Managing Director of Communications 
225-299-3708 
[email protected] 

Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 10.02
THC's Forward PE Ratio is ranked higher than
83% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 19.88 vs. THC: 10.02 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 55.64
THC's PB Ratio is ranked lower than
75% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 2.62 vs. THC: 55.64 )
Ranked among companies with meaningful PB Ratio only.
THC' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 5.23 Max: 100.25
Current: 55.64
1.39
100.25
PS Ratio 0.07
THC's PS Ratio is ranked higher than
98% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. THC: 0.07 )
Ranked among companies with meaningful PS Ratio only.
THC' s PS Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.29 Max: 0.57
Current: 0.07
0.05
0.57
Price-to-Free-Cash-Flow 5.64
THC's Price-to-Free-Cash-Flow is ranked higher than
80% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 22.48 vs. THC: 5.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
THC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.06  Med: 37.36 Max: 848.55
Current: 5.64
2.06
848.55
Price-to-Operating-Cash-Flow 3.22
THC's Price-to-Operating-Cash-Flow is ranked higher than
93% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 14.62 vs. THC: 3.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
THC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.31  Med: 6.27 Max: 15.64
Current: 3.22
1.31
15.64
EV-to-EBIT 22.57
THC's EV-to-EBIT is ranked higher than
71% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 20.85 vs. THC: 22.57 )
Ranked among companies with meaningful EV-to-EBIT only.
THC' s EV-to-EBIT Range Over the Past 10 Years
Min: -273.8  Med: 14.2 Max: 1337.9
Current: 22.57
-273.8
1337.9
EV-to-EBITDA 10.25
THC's EV-to-EBITDA is ranked higher than
85% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 15.17 vs. THC: 10.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
THC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.1  Med: 8.4 Max: 22.6
Current: 10.25
-22.1
22.6
EV-to-Revenue 0.86
THC's EV-to-Revenue is ranked higher than
83% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.18 vs. THC: 0.86 )
Ranked among companies with meaningful EV-to-Revenue only.
THC' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 0.9 Max: 1.4
Current: 0.86
0.5
1.4
Shiller PE Ratio 46.92
THC's Shiller PE Ratio is ranked higher than
51% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 27.79 vs. THC: 46.92 )
Ranked among companies with meaningful Shiller PE Ratio only.
THC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.33  Med: 47.11 Max: 332.1
Current: 46.92
20.33
332.1
Current Ratio 1.28
THC's Current Ratio is ranked lower than
57% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.41 vs. THC: 1.28 )
Ranked among companies with meaningful Current Ratio only.
THC' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.48 Max: 2.38
Current: 1.28
0.88
2.38
Quick Ratio 1.21
THC's Quick Ratio is ranked lower than
57% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. THC: 1.21 )
Ranked among companies with meaningful Quick Ratio only.
THC' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.39 Max: 2.29
Current: 1.21
0.85
2.29
Days Inventory 9.34
THC's Days Inventory is ranked higher than
70% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 16.86 vs. THC: 9.34 )
Ranked among companies with meaningful Days Inventory only.
THC' s Days Inventory Range Over the Past 10 Years
Min: 8.92  Med: 10.35 Max: 13.35
Current: 9.34
8.92
13.35
Days Sales Outstanding 46.67
THC's Days Sales Outstanding is ranked lower than
65% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 41.26 vs. THC: 46.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
THC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.67  Med: 53.87 Max: 62.54
Current: 46.67
46.67
62.54
Days Payable 32.40
THC's Days Payable is ranked lower than
58% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: 51.14 vs. THC: 32.40 )
Ranked among companies with meaningful Days Payable only.
THC' s Days Payable Range Over the Past 10 Years
Min: 32.4  Med: 47.66 Max: 56.74
Current: 32.4
32.4
56.74

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
THC's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. THC: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
THC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.2  Med: -0.8 Max: 7.3
Current: -1
-22.2
7.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.56
THC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 1.98 vs. THC: 0.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
THC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.14 Max: 222.62
Current: 0.56
0.55
222.62
Price-to-Median-PS-Value 0.24
THC's Price-to-Median-PS-Value is ranked higher than
97% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. THC: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
THC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 1.88 Max: 6.19
Current: 0.24
0.22
6.19
Earnings Yield (Greenblatt) % 4.41
THC's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. THC: 4.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
THC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.8  Med: 6.6 Max: 15.7
Current: 4.41
-9.8
15.7
Forward Rate of Return (Yacktman) % 37.28
THC's Forward Rate of Return (Yacktman) % is ranked higher than
93% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 8.93 vs. THC: 37.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
THC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -103.1  Med: 0.6 Max: 39
Current: 37.28
-103.1
39

More Statistics

Revenue (TTM) (Mil) $19,061.00
EPS (TTM) $ -5.51
Beta1.05
Short Percentage of Float45.33%
52-Week Range $12.25 - 22.72
Shares Outstanding (Mil)100.94

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19,223 19,604 20,201
EPS ($) 0.56 1.01 2.36
EPS without NRI ($) 0.56 1.01 2.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
28.21%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}